Brangre Vasseur - OSE Pharma Chief ImmunoOncology

All Insiders . France . 
Stock . OSE Pharma SA . Stakeholders . Insider . Brangre Vasseur
OSE Stock  EUR 8.89  0.21  2.42%   

Insider

Brangre Vasseur is Chief ImmunoOncology of OSE Pharma SA
Phone33 2 28 29 10 10
Webhttps://www.ose-immuno.com

OSE Pharma Management Efficiency

The company has return on total asset (ROA) of (0.0528) % which means that it has lost $0.0528 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1482) %, meaning that it generated substantial loss on money invested by shareholders. OSE Pharma's management efficiency ratios could be used to measure how well OSE Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
OSE Pharma SA has accumulated 34.77 M in total debt with debt to equity ratio (D/E) of 7.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. OSE Pharma SA has a current ratio of 2.49, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist OSE Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, OSE Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OSE Pharma SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OSE to invest in growth at high rates of return. When we think about OSE Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Valerie LeyldeBiomerieux SA
N/A
Laurent LebrasEurofins Scientific SE
N/A
Timothy OostdykEurofins Scientific SE
N/A
Cyril BuxtorfSEB SA
57
Sylvain MorgeauBiomerieux SA
N/A
Heiko ImhlSartorius Stedim Biotech
N/A
Delphine VayletSEB SA
53
Joachim ReicheltEurofins Scientific SE
N/A
Alexandre MerieuxBiomerieux SA
49
Giles PelissierSEB SA
N/A
Pierre BouludBiomerieux SA
52
Martin ZouharSEB SA
N/A
Franois LacosteBiomerieux SA
N/A
Frederic BesemeBiomerieux SA
67
Valerie HanoteEurofins Scientific SE
57
Philippe SumeireSEB SA
61
Benedikt OrzelekSartorius Stedim Biotech
N/A
David BryantEurofins Scientific SE
N/A
Philippe SchailleeSEB SA
N/A
John MackaySartorius Stedim Biotech
61
Sandra HoeylaertsEurofins Scientific SE
N/A
OSE Immunotherapeutics SA, a biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. OSE Immunotherapeutics SA is headquartered in Nantes, France. OSE IMMUNO operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 34 people. OSE Pharma SA (OSE) is traded on Euronext Paris in France and employs 60 people.

Management Performance

Return On Equity-0.15
Return On Asset-0.0528

OSE Pharma SA Leadership Team

Elected by the shareholders, the OSE Pharma's board of directors comprises two types of representatives: OSE Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OSE. The board's role is to monitor OSE Pharma's management team and ensure that shareholders' interests are well served. OSE Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OSE Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Brangre Vasseur, Chief ImmunoOncology
Alain MD, Medical Director
Silvia MD, Head Devel
Nicolas Poirier, Scientific Director
AnneLaure AutretCornet, Chief Financial and Administrative Officer
JeanPascal PharmD, Chief Person
Dominique MD, Chairman Founder
Alexis Peyroles, Consultant
Julien Perrier, Chief Commercial Officer
Linda MSc, Chief Officer

OSE Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OSE Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.15
Return On Asset-0.0528
Profit Margin(0.22) %
Operating Margin(0.25) %
Current Valuation128.18 M
Shares Outstanding18.44 M
Shares Owned By Insiders39.03 %
Shares Owned By Institutions1.81 %
Price To Earning10.60 X
Price To Book2.64 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Other Information on Investing in OSE Stock

OSE Pharma financial ratios help investors to determine whether OSE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in OSE with respect to the benefits of owning OSE Pharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY